Clinical Trial Search

Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants

Primary: Number of Participants With Lab Testing Acceptability Survey Scores >80% — 7; 41; 7; 40 Participants

Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants

Primary: HBsAG Prevalence — 22 Participants

Primary: Presence of Rotavirus Vaccine Strain in Any Stool Sample From Twin Receiving Placebo. — 15 subjects

Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants

Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Dried Blood Spot Analysis of Medication Adherence- Mother and Infant — 56; 157; 35; 183 Participants

Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates

Primary: Antepartum Component: Number of Confirmed Infant HIV Infections — 25; 7; 2 Participants

Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Utilization of Postpartum Contraception — 199; 213 participants — p=<0.05

Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain — 13; 29 neonatal S. aureus infections

Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years

Primary: Frequency of Adverse Events in the CHMI-trans Model — 95; 95; 107; 52 Adverse events

Primary: HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study — 8; 18; 700; 699 participants — p=0.049

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment — 15.03; 14.93 events per…

Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions

Primary: Rate of Influenza Vaccination — 2382; 2496 participants

Primary: Rate of COVID-19 Vaccination (6 Month) — 251; 130 Participants

Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42

Primary: Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group — 98; 148; 82; 46 Participants

Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001

Primary: Number of Participants With Virologic Suppression — 274; 256; 160 Participants

Primary: Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery — .84; .94 Proportion — p=0.001